Health
AstraZeneca’s COVID-19 vaccine candidate begins late-stage U.S. study – Reuters India
AstraZeneca Plc said on Monday it has begun enrolling adults for a U.S.-funded, 30,000-subject late-stage study of its high profile COVID-19 vaccine candidate.
By Reuters Staff
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo
(Reuters) – AstraZeneca Plc said on Monday it has begun enrolling adults for a U.S.-funded, 30,000-subject late-stage study of its high profile COVID-19 vaccine candidate.
Trial participants will receive either two doses of the experimental vaccine, dubbed AZD1222, …
-
Business16 hours agoWhy did this ASX 200 healthcare stock crash 14% yesterday?
-
General24 hours agoRussia launches hundreds of drones and missiles against Ukraine in fresh attack
-
Business19 hours agoOwn Xero shares? Here are 3 key takeaways from its AGM
-
General16 hours agoPatients speak out after Brisbane doctor accused of ‘excessive’ pap smears, kissing woman on lips